Xeris Pharmaceuticals Inc. (XERS) Tops Q2 EPS by 3c
Get Alerts XERS Hot Sheet
Join SI Premium – FREE
Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $25.3 million versus the consensus estimate of $26.1 million.
GUIDANCE:
Xeris Pharmaceuticals Inc. sees FY2022 revenue of $105-120 million.
For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First Industrial Realty (FR) Tops Q1 EPS by 21c
- Triumph Financial, Inc. (TFIN) Misses Q1 EPS by 20c
- Old Second Bancorp (OSBC) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!